



Executive Summary

Management

- Ran Vigdor (LL.B, MBA) - **CEO**
- Beatriz Palacios (PharmD, PhD)
- **Development Director**
- Nicholas L. Occleston (PhD)
- **Discovery Director**

Key Advantages

- Experienced team
- Virtual, cost effective structure
- Clear market and industry needs
- Network of research institutions

Recent Achievements

- FDA Approval for First-in-Man study (Sep., 2010)
- Top 5 biotechnology investment opportunities in Spain (BioSpain Oct., 2010)
- In-license agreement signed (July, 2012)
- Secured €2M funding (Dec., 2012)
- TCD-717 Phase I Last-Patient-Out (February, 2014)



Vision: build Traslational Cancer Drugs Pharma S.L (“TCD” or the “Company”) as an **Oncology specialty pharma**.

Mission: to create value for the shareholders who believe in us, and the communities we live in, by developing **innovative drugs** that address unmet medical needs in the field of Oncology and provide clinical benefits to millions of patients worldwide.

Strategy: TCD’s strategy is to **identify, evaluate and in-license breakthrough discoveries** from academic research institutions and to rapidly advance them through the completion of Phase II of the Regulatory process. This is done by leveraging resources through collaborations and outsourcing, resulting in an **efficient, flexible and effective process**. Value to shareholders is generated by royalty-bearing licensing agreements.

First Target: TCD’s leading target is Choline Kinase Alpha (ChoK α), an enzyme regulating the production of phosphatidylcholine (a key building block in the formation of the cell’s membrane). TCD has demonstrated that ChoK α is a treatment target of unique quality. Not only can ChoK α be used for treatment of patients suffering from a **broad variety of tumors**, but also inhibition of ChoK α while merely arresting temporarily the life cycle of normal cells is toxic to cancer cells.

First Product: TCD-717 is the Company’s leading product. This **first-in-class**, precisely-targeted ChoK α inhibitor is a small molecule that has demonstrated significant efficacy and a favorable therapeutic index in various cancer types both *in-vitro* and *in-vivo*.



Previous Rounds

- Invested to date: ≈ €12,400,000
- Seed Round (Class A) €755,000
- 1st Round (Class B) €1,650,000
- 2nd Round (Class B) €6,000,000
- Other ≈ €4,000,000

Current Shareholders

- Cross Road Biotech, S.A. S.C.R.
- Fondo Tecnológico Seguranza
- Real De Vellón, S.A. S.C.R.
- ADE Gestion Sodical SGEGR
- Oncopharma ,S.L.

Investment Required

€20 million in two parts:

- €4-€ 5 Million in a bridge round
- €15 international round

Use of Funds

- Carry out Phase II with TCD-717
- Pipeline expansion



Status: A Phase I study, for evaluating the safety and tolerability of TCD-717 as a treatment for solid tumors, has been concluded. The study was carried out in two leading medical centers in the USA *in accordance with FDA approval*. The final report of the study is expected in Q2 2014 however, a clear therapeutic window has been demonstrated and activity signs observed.

Pipeline: TCD is currently positioning itself as a Spain's *Partner of Choice* for Oncology drug discovery and development opportunities. The aim of the Company is to build its pipeline through in-licensing of cutting edge technology, with clear commercial rationale. In doing so TCD capitalizes on the high quality innovative research currently conducted in Spain, for which there are limited early stage commercialization and funding options available. In 2012-2013 TCD signed two agreements with leading research institutions licensing one product and securing a preferential right for another.

A View to 2018: by the end of 2018 TCD would have one drug candidate at the end of Phase II (TCD-717) and three additional programs in different stages of Phase I.

The Opportunity: ChoK α and TCD-717 with large target markets and strong IP position insure value to shareholders. TCD's strong management team with extensive experience and expertise, together with its unique relationship with key research institutions in Spain and the promise of new discoveries, offers shareholders clear and untapped potential.



For more information:

info@tcdpharma.com

Visit us at www.tcdpharma.com

Follow us on Twitter [@TCD Pharma](https://twitter.com/TCD_Pharma)

